Energy, Real Estate stocks rebound as ASX rises
Dip buying is driving the ASX higher today as sold down sectors climbed on Wednesday.
Stockhead
All you need to know before the ASX opens
Here’s everything you need to know before the ASX opens today.
ASX health stocks dip, but recover
ASX health stocks regained ground on Friday but, at the time of publishing, fell by 0.37% overall. Yep, it’s been a volatile old week.
Forgotten biotech stocks soar
The biotech sector is fast emerging from its two-year funk amid a rush of news about clinical trials, approvals and capital raisings.
More Stories
Everything you need to know before the ASX opens
Good morning, and Happy Friday! Here’s everything you need to know before the ASX opens today.
VMS scores big rare earths hit at Jupiter
Drilling at Venture Minerals’ Jupiter rare earths discovery has returned a record-breaking intersection of 57m at 3430ppm TREO.
Closing Bell: ASX 200 brings home unlikely win as gold and Utilities soar, A2 Milk sours
The Aussie benchmark closed marginally higher today, with goldies and Utilities doing the heavy lifting
ASX Small Caps Lunch Wrap
Local markets have risen slightly this morning, on the heels of Wall Street’s eighth win on the trot.
Miners boost ASX; Yancoal Falls on dividend halt
Coal miner Yancoal surprised investors after announcing it won’t pay dividends soon, despite a strong half-year profit.
Disposable miners shielding Pilbara iron ore
BHP thinks a proliferation of small, disposable iron ore producers is shielding the Pilbara iron ore giants.
New tech boosts Parkinson’s detection
Inoviq’s NEURO-NET technology is now further validated for isolating brain-derived exosomes in Parkinson’s disease.
All you need to know before the ASX opens
Here’s everything you need to know, and some things you don’t, before the ASX opens today.
Chalice Mining’s green light for Gonneville
Stockhead TV’s Sarah Hughan brings you today’s Break it Down, detailing the new government recognition for Chalice’s Gonneville.
Botanix eyes huge US anti-sweating market
Botanix is targeting a US market of 10 million patients with its anti-sweating drug.
Original URL: https://www.ntnews.com.au/business/stockhead/page/196